Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2066 effect on TLESRs in healthy subjects
NCT00813306Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AZD-2066 in gastroesophageal reflux disease (GERD), sponsored by AstraZeneca. Started Dec 2008; status: completed.
02
Drugs
AZD-2066
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00813306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00813306.